Volume 89 Issue 24 | p. 19 | Concentrates
Issue Date: June 13, 2011

Pfizer Signs Cancer Candidate To Clovis

Department: Business
Keywords: oncology, Pfizer, Clovis

Clovis Oncology and Pfizer have signed an agreement under which Clovis will assume responsibility for Pfizer’s oral and intravenous poly(ADP-ribose) polymerase (PARP) inhibitor, PF-01367338, a small-molecule therapeutic currently in Phase I and II development programs for solid tumors. Pfizer will receive an undisclosed equity stake in Clovis and milestone payments of up to $255 million. “Clovis Oncology is the ideal choice to continue the development and commercialization of PF-01367338,” says Garry Nicholson, president and general manager of Pfizer Oncology.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment